Alpha particle

Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023

Retrieved on: 
Thursday, March 14, 2024
CD33, GSK, Patient, Macrophage, Society, CD3, CD47, DLL3, Therapy, Molecular Partners, TME, Partner, DRS, ASH, AML, SNMMI, Partnership, RDT, Radionuclide, Tetra, Novartis, HSCT, MHS, FTE, Exposition, Delta, Safety, SITC, Amgen, Hematopoietic stem cell transplantation, FAP, Disease, Nuclear medicine, Immunotherapy, District court, Neoplasm, EANM, Alpha particle, JNJ, Tumor microenvironment, Gene family, CD70, AACR, CD40, CHF, CD123, NK, Engineering, Antigen, Molecule, Annual general meeting, Toxicity, CD16, B cell, Conference, MBA, DARPin, Data, Molecular imaging, Pharmaceutical industry

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and audited financial results for the full year 2023.

Key Points: 
  • 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and audited financial results for the full year 2023.
  • “2023 was a year of successful innovation and execution on our strategy, focusing on novel mechanisms that we believe only DARPin therapies can deliver.
  • In addition to the above updates, Molecular Partners continued to progress its RDT portfolio of projects in partnership with Novartis.
  • In the financial year 2023, Molecular Partners recognized total revenues and other income of CHF 7.0 million (2022: CHF 189.6 million) and incurred total expenses of CHF 68.1 million (2022: CHF 73.0 million).

AdvanCell Announces First Patient Dosed in Phase I/II TheraPb Clinical Trial of 212Pb-ADVC001 in Metastatic Prostate Cancer

Retrieved on: 
Tuesday, November 7, 2023
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Alpha particle, Prostate, Prostate cancer, MD, University of California, San Francisco, University, Peter MacCallum Cancer Centre, University of California, Los Angeles, Cancer, Targeted alpha-particle therapy, PSMA, Patient, Letter, Medical imaging, Pharmaceutical industry

“The first patient dosed with an AdvanCell therapeutic candidate represents a major milestone for the Company, our scientists, clinical trial sites, and our patients,” said Andrew Adamovich, CEO of AdvanCell.

Key Points: 
  • “The first patient dosed with an AdvanCell therapeutic candidate represents a major milestone for the Company, our scientists, clinical trial sites, and our patients,” said Andrew Adamovich, CEO of AdvanCell.
  • “We believe that 212Pb is the ideal radioisotope to realise the full therapeutic power of Targeted Alpha Therapy.
  • “We are excited to be moving this 212Pb-based therapy forward in the TheraPb clinical study.”
    Developed the world’s first 212Pb-based Targeted Alpha Therapy to enter clinical trials in metastatic prostate cancer.
  • Developed a proprietary target discovery and ligand development program encompassing a robust pipeline of Targeted Alpha Therapies to treat cancer.

CNL’S Vision to Become a World Leader in Actinium-225 is Coming to Life

Retrieved on: 
Thursday, February 2, 2023
Nuclear medicine, Nuclear, Good laboratory practice, Atomic Energy of Canada Limited, Safety, International, Atomic energy, Cancer, Triangle Universities Nuclear Laboratory, CNL, ITM, Active ingredient, TAT, Isotope, Teva Active Pharmaceutical Ingredients, Actinium-225, Hope, API, Chalk River Laboratories, Radiobiology, Radiopharmaceutical, Alpha particle, Research, Fine chemical, Medical imaging

CHALK RIVER, Ontario, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada’s premier nuclear science and technology laboratory, is celebrating a key milestone in its vision to become a world leader in the research and production of Actinium-225, a promising but very rare medical isotope. The end of 2022 marked five years since the first successful shipment of Actinium-225, and CNL has been shipping this product successfully and reliably ever since, which recently included its 100th shipment. Furthermore, CNL has realized steady progress during that same time, including establishing research-scale production facilities at the Chalk River Laboratories campus, implementing international standards to perform pre-clinical research at the site, and securing a global network of partners needed to eventually deliver a stable, commercial supply of the isotope.

Key Points: 
  • CNL is now working to position itself as a world leader and international hub for targeted alpha therapy (TAT) and for the production of the extremely rare and promising Actinium-225 isotope.
  • Both of these accomplishments position CNL to advance research related to TAT and Actinium-225 on its campus and using its own materials.
  • As Actinium-225 decays, it emits high-energy alpha particles that effectively kill cancer cells, leaving nearby healthy cells unharmed in the process.
  • To learn more about CNL, including its work in health sciences, please visit www.cnl.ca .

THE PROSTATE CANCER FOUNDATION ANNOUNCES 2022 YOUNG INVESTIGATOR AWARDS TOTALING $7.2 MILLION FOR PROSTATE CANCER RESEARCH

Retrieved on: 
Wednesday, October 26, 2022
Quality of life, Physician, Disease, Prostate, Prostate cancer, Genetic testing, Patient, Metastasis, AIM, Research, PCF, Military medicine, Prostate Cancer Foundation, Henry M. Jackson Foundation for the Advancement of Military Medicine, Outline of health sciences, Alpha particle, Death, Center, National Institute of Environmental Health Sciences, Exercise, Pharmaceutical industry, Medical imaging, Veteran, Doctor of Philosophy

LOS ANGELES, Oct. 26, 2022 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) today announced the Class of 2022 Young Investigator Award recipients totaling $7.2 million in funding for innovative prostate cancer research.

Key Points: 
  • LOS ANGELES, Oct. 26, 2022 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) today announced the Class of 2022 Young Investigator Award recipients totaling $7.2 million in funding for innovative prostate cancer research.
  • PCF Young Investigator Awards are intended to identify a cohort of future research leaders who will keep the field of prostate cancer research vibrant with new ideas and offer career and project support for early career physicians and scientists who are committed to advancing the prostate cancer field.
  • Thirty-four PCF Young Investigator Awards totaling $7.2 million were granted to the promising next generation of cancer researchers.
  • PCF is committed to creating a global public square for prostate cancer, in service to our mission of ending death and suffering from the disease.

AdvanCell Closes A$18M Series B Funding Led by Morningside

Retrieved on: 
Wednesday, August 24, 2022
Research, Men, Biotechnology, Radiology, General Health, Pharmaceutical, Consumer, Health, Science, Oncology, Radiochemistry, Hamstringing, Technology, CEO, Research, Federal, Alpha particle, Director, Board, Chair, Course, Isotope, Social responsibility, Targeted alpha-particle therapy, Australian Nuclear Science and Technology Organisation, Company, Research and Development Tax Incentive, Element, Coronavirus Scientific Advisory Board (Turkey), ANSTO, Founder, Alpha, Growth, Adoption, Patient, Pharmaceutical industry, Management, Medical imaging, Cancer

AdvanCell, an Australian radiopharmaceutical company with a platform technology for a revolutionary cancer treatment called Targeted Alpha Therapy, announced today the closing of an A$18 million Series B financing round led by Morningside.

Key Points: 
  • AdvanCell, an Australian radiopharmaceutical company with a platform technology for a revolutionary cancer treatment called Targeted Alpha Therapy, announced today the closing of an A$18 million Series B financing round led by Morningside.
  • AdvanCell believes this precise and powerful treatment will rapidly become a leading pillar of cancer treatment, providing treatments for diseases for which there are currently no effective options.
  • AdvanCell has a world-class team and is honoured to be advised by an outstanding Board of Directors and Scientific Advisory Board.
  • For more information visit www.advancell.com.au
    Founded in 1986 by the Chan family, Morningside is a technology and life science venture investment firm.

Alpha Tau Medical Appoints Jefferson University Radiation Oncologist Robert Den as Chief Medical Officer

Retrieved on: 
Wednesday, September 4, 2019
Physical sciences, Natural sciences, Chemistry, Radioactivity, Helium, Chemical elements, Medical physics, Alpha particle, Ionizing radiation, Radioactive decay, Radiation, Alpha decay

TEL AVIV, Israel, Sept. 4, 2019 /PRNewswire/ -- Alpha Tau Medical , developer of the breakthrough alpha radiation cancer therapy Alpha DaRT, announced today the appointment of Dr. Robert B. Den, MD, as Chief Medical Officer (CMO).

Key Points: 
  • TEL AVIV, Israel, Sept. 4, 2019 /PRNewswire/ -- Alpha Tau Medical , developer of the breakthrough alpha radiation cancer therapy Alpha DaRT, announced today the appointment of Dr. Robert B. Den, MD, as Chief Medical Officer (CMO).
  • Dr. Den attended Yale University, and received his medical degree from Harvard Medical School in 2006.
  • "I am glad to see leaders in their fields continuing to join Alpha Tau," said Uzi Sofer, CEO of Alpha Tau Medical.
  • Alpha DaRT (Diffusing Alpha-Emitters Radiation Therapy) delivers high-precision alpha radiation that is released when radioactive substances decay inside the tumor.

Kanazawa University Research: Radioisotope Couple for Tumor Diagnosis and Therapy

Retrieved on: 
Wednesday, May 8, 2019
Physical sciences, Natural sciences, Chemistry, Radioactivity, Radiobiology, Astatine, Kanazawa University, Alpha particle, Radioactive tracer, Ionizing radiation, Radiation therapy, Radionuclide

In recent years, an approach combining therapy and diagnosis both based on radioisotopes, called 'radiotheranostics', has gained significance.

Key Points: 
  • In recent years, an approach combining therapy and diagnosis both based on radioisotopes, called 'radiotheranostics', has gained significance.
  • Now, Kazuma Ogawa from Kanazawa University and colleagues have synthesized a radiotheranostic system with astatine (At-211) as the alpha-particle emitter and iodine (I-123) as the gamma-radiation source.
  • The University is located on the coast of the Sea of Japan in Kanazawa a city rich in history and culture.
  • Kanazawa University is divided into two main campuses: Kakuma and Takaramachi for its approximately 10,200 students including 600 from overseas.

Kanazawa University Research: Radioisotope Couple for Tumor Diagnosis and Therapy

Retrieved on: 
Wednesday, May 8, 2019
Physical sciences, Natural sciences, Chemistry, Radioactivity, Radiobiology, Astatine, Kanazawa University, Alpha particle, Radioactive tracer, Ionizing radiation, Radiation therapy, Radionuclide

In recent years, an approach combining therapy and diagnosis both based on radioisotopes, called 'radiotheranostics', has gained significance.

Key Points: 
  • In recent years, an approach combining therapy and diagnosis both based on radioisotopes, called 'radiotheranostics', has gained significance.
  • Now, Kazuma Ogawa from Kanazawa University and colleagues have synthesized a radiotheranostic system with astatine (At-211) as the alpha-particle emitter and iodine (I-123) as the gamma-radiation source.
  • The University is located on the coast of the Sea of Japan in Kanazawa a city rich in history and culture.
  • Kanazawa University is divided into two main campuses: Kakuma and Takaramachi for its approximately 10,200 students including 600 from overseas.

Breakthrough Cancer Therapy Developer, Alpha Tau, Awarded ISO 13485 Certificate for Quality Management of Medical Devices

Retrieved on: 
Thursday, April 11, 2019
Physical sciences, Natural sciences, Radioactivity, Radiobiology, Branches of biology, Medical technology, ISO 13485, Medical equipment, BSI Group, Alpha particle, Medical device, Ionizing radiation

TEL AVIV, Israel, April 11, 2019 /PRNewswire/ -- Alpha Tau Medical , developer of the breakthrough alpha radiation cancer therapy, Alpha DaRT, announced today that it has obtained ISO 13485:2016 certification.

Key Points: 
  • TEL AVIV, Israel, April 11, 2019 /PRNewswire/ -- Alpha Tau Medical , developer of the breakthrough alpha radiation cancer therapy, Alpha DaRT, announced today that it has obtained ISO 13485:2016 certification.
  • The certification was awarded following an audit by the UK's independent national compliance body, British Standards Institution (BSI) .
  • ISO 13485:2016 is the internationally-recognized quality standard to ensure the consistent design, development, production, installation and sale of medical devices that are safe for their intended purposes.
  • Founded in 2016, Alpha Tau Medical Ltd. is an Israeli biotech company that focuses on R&D and commercialization of the first alpha-radiation based cancer treatment for solid tumors, Alpha DaRT.

Cancer Biotech Firm Alpha Tau Medical Appoints Raphi Levy of Goldman Sachs as Chief Financial Officer

Retrieved on: 
Tuesday, March 26, 2019
National Panhellenic Conference, Proteins, Tau protein, Alpha Sigma Tau, Alpha particle, Radiation

TEL AVIV, Israel, March 26, 2019 /PRNewswire/ -- Alpha Tau Medical , developer of the breakthrough alpha radiation cancer therapy, Alpha DaRT, announced today that Mr. Raphi Levy will be joining Alpha Tau's management team as Chief Financial Officer.

Key Points: 
  • TEL AVIV, Israel, March 26, 2019 /PRNewswire/ -- Alpha Tau Medical , developer of the breakthrough alpha radiation cancer therapy, Alpha DaRT, announced today that Mr. Raphi Levy will be joining Alpha Tau's management team as Chief Financial Officer.
  • Mr. Levy commented, "I am thrilled to join Alpha Tau and take part in a revolutionary new therapy for cancer patients.
  • "We are proud to attract world-class professionals to join the Alpha Tau team," added Uzi Sofer, CEO of Alpha Tau Medical.
  • Founded in 2016, Alpha Tau Medical Ltd. is an Israeli biotech company that focuses on R&D and commercialization of the first alpha-radiation based cancer treatment for solid tumors, Alpha DaRT.